SG11202109563WA - Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction - Google Patents
Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunctionInfo
- Publication number
- SG11202109563WA SG11202109563WA SG11202109563WA SG11202109563WA SG11202109563WA SG 11202109563W A SG11202109563W A SG 11202109563WA SG 11202109563W A SG11202109563W A SG 11202109563WA SG 11202109563W A SG11202109563W A SG 11202109563WA SG 11202109563W A SG11202109563W A SG 11202109563WA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- pathway inhibitors
- chronic lung
- lung allograft
- allograft dysfunction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814085P | 2019-03-05 | 2019-03-05 | |
| PCT/US2020/021088 WO2020181034A1 (en) | 2019-03-05 | 2020-03-05 | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109563WA true SG11202109563WA (en) | 2021-09-29 |
Family
ID=69941525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109563WA SG11202109563WA (en) | 2019-03-05 | 2020-03-05 | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11406640B2 (zh) |
| EP (1) | EP3934651A1 (zh) |
| JP (1) | JP2022524997A (zh) |
| KR (1) | KR20210137087A (zh) |
| CN (1) | CN114007621A (zh) |
| AU (1) | AU2020232757A1 (zh) |
| CA (1) | CA3132371A1 (zh) |
| EA (1) | EA202192426A1 (zh) |
| IL (1) | IL285999A (zh) |
| MA (1) | MA55201A (zh) |
| MX (1) | MX2021010545A (zh) |
| SG (1) | SG11202109563WA (zh) |
| WO (1) | WO2020181034A1 (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019335200A1 (en) | 2018-09-04 | 2021-03-11 | Theravance Biopharma R&D Ip, Llc | 5 to 7 membered heterocyclic amides as JAK inhibitors |
| IL281146B2 (en) | 2018-09-04 | 2023-12-01 | Theravance Biopharma R& D Ip Llc | Dimethyl amino aztidine amides as JAK inhibitors |
| EP3853229A1 (en) | 2018-10-29 | 2021-07-28 | Theravance Biopharma R&D IP, LLC | 2-azabicyclo hexane compound as jak inhibitor |
| CA3117969A1 (en) | 2018-10-31 | 2020-05-07 | Incyte Corporation | Combination therapy for treatment of hematological diseases |
| CN114007621A (zh) | 2019-03-05 | 2022-02-01 | 因赛特公司 | 用于治疗慢性肺同种异体移植物功能障碍的jak1途径抑制剂 |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| TW202144343A (zh) | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
| KR20230053831A (ko) | 2021-10-15 | 2023-04-24 | 주식회사 엘지에너지솔루션 | 용접봉 체결 방법 및 이에 의해 용접봉이 수직으로 체결된 용접 장치 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL153231A0 (en) | 2000-06-28 | 2003-07-06 | Smithkline Beecham Plc | Wet milling process |
| PT3184526T (pt) | 2005-12-13 | 2018-12-19 | Incyte Holdings Corp | Derivados de pirrolo[2,3-d]pirimidina como inibidores da cinase janus |
| JP2009529539A (ja) | 2006-03-07 | 2009-08-20 | エンダセア， インコーポレイテッド | 呼吸器障害を治療するための方法および組成物 |
| US8058227B2 (en) | 2006-10-03 | 2011-11-15 | Medical University Of South Carolina | Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD |
| US20080312259A1 (en) | 2007-06-13 | 2008-12-18 | Incyte Corporation | SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE |
| KR20100135909A (ko) | 2008-04-17 | 2010-12-27 | 사노피-아벤티스 | 심혈관성 입원 또는 사망을 예방하는데 사용하기 위한 약제의 제조에 있어서의 드로네다론의 용도 |
| US8426411B2 (en) | 2008-06-10 | 2013-04-23 | Abbott Laboratories | Tricyclic compounds |
| ES2487542T3 (es) | 2009-05-22 | 2014-08-21 | Incyte Corporation | Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus |
| AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
| TWI766281B (zh) | 2010-03-10 | 2022-06-01 | 美商英塞特控股公司 | 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物 |
| CN103442568A (zh) | 2010-10-08 | 2013-12-11 | Abbvie公司 | 呋喃并[3,2-d]嘧啶化合物 |
| AR083933A1 (es) | 2010-11-19 | 2013-04-10 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
| JP5917544B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン |
| EA201490042A1 (ru) | 2011-06-20 | 2014-10-30 | Инсайт Корпорейшн | Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| AR091079A1 (es) | 2012-05-18 | 2014-12-30 | Incyte Corp | Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak |
| US20150197525A1 (en) | 2012-06-15 | 2015-07-16 | Concert Pharmaceuticals, Inc. | Deuterated derivatives of ruxolitinib |
| BR112015003153A2 (pt) | 2012-08-17 | 2017-07-04 | Concert Pharmaceuticals Inc | baricitinib deuterado |
| CN107936039A (zh) | 2012-11-01 | 2018-04-20 | 因赛特公司 | 作为jak抑制剂的三环稠合噻吩衍生物 |
| HUE057262T2 (hu) | 2013-03-06 | 2022-04-28 | Incyte Holdings Corp | Eljárás és köztitermékek JAK inhibitor elõállítására |
| PL3786162T3 (pl) | 2013-05-17 | 2024-04-08 | Incyte Holdings Corporation | Pochodne bipirazolu jako inhibitory jak |
| US9655854B2 (en) * | 2013-08-07 | 2017-05-23 | Incyte Corporation | Sustained release dosage forms for a JAK1 inhibitor |
| AU2014339897A1 (en) * | 2013-10-24 | 2016-04-21 | Abbvie Inc. | JAK1 selective inhibitor and uses thereof |
| PE20161388A1 (es) * | 2014-02-28 | 2016-12-28 | Incyte Corp | Inhibidores de la jak1 para el tratamiento de sindromes mielodisplasicos |
| MA39987A (fr) | 2014-04-30 | 2017-03-08 | Incyte Corp | Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| CA3001542C (en) | 2015-11-03 | 2021-02-16 | Theravance Biopharma R&D Ip, Llc | Jak kinase inhibitor compounds for treatment of respiratory disease |
| CN105294699B (zh) * | 2015-12-04 | 2019-06-11 | 上海勋和医药科技有限公司 | 巴瑞替尼的制备方法 |
| RS62695B1 (sr) * | 2016-10-03 | 2022-01-31 | Highlightll Pharmaceutical Hainan Co Ltd | Novi jak1 selektivni inhibitori i njihove upotrebe |
| EP3327020A1 (en) | 2016-11-29 | 2018-05-30 | Sandoz Ag | Citrate salts of a janus kinase (jak) inhibitor |
| SG11201907840RA (en) | 2017-03-09 | 2019-09-27 | Theravance Biopharma R&D Ip Llc | Fused imidazo-piperidine jak inhibitors |
| AU2018261588A1 (en) | 2017-05-01 | 2019-10-31 | Theravance Biopharma R&D Ip, Llc | Methods of treatment using a JAK inhibitor compound |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| CN112105608B (zh) | 2018-01-30 | 2023-07-14 | 因赛特公司 | 制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法 |
| EP3752146A1 (en) | 2018-02-16 | 2020-12-23 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of cytokine-related disorders |
| AU2019245420A1 (en) | 2018-03-30 | 2020-11-12 | Incyte Corporation | Treatment of hidradenitis suppurativa using JAK inhibitors |
| MA52208A (fr) | 2018-04-13 | 2021-02-17 | Incyte Corp | Biomarqueurs pour une maladie du greffon contre l'hôte |
| CA3117969A1 (en) | 2018-10-31 | 2020-05-07 | Incyte Corporation | Combination therapy for treatment of hematological diseases |
| CA3123596A1 (en) | 2018-12-19 | 2020-06-25 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of gastrointestinal disease |
| CN114007621A (zh) | 2019-03-05 | 2022-02-01 | 因赛特公司 | 用于治疗慢性肺同种异体移植物功能障碍的jak1途径抑制剂 |
| EP3941474A2 (en) | 2019-03-19 | 2022-01-26 | Incyte Corporation | Biomarkers for vitiligo |
-
2020
- 2020-03-05 CN CN202080024215.0A patent/CN114007621A/zh active Pending
- 2020-03-05 EA EA202192426A patent/EA202192426A1/ru unknown
- 2020-03-05 SG SG11202109563WA patent/SG11202109563WA/en unknown
- 2020-03-05 WO PCT/US2020/021088 patent/WO2020181034A1/en active Application Filing
- 2020-03-05 CA CA3132371A patent/CA3132371A1/en active Pending
- 2020-03-05 US US16/810,045 patent/US11406640B2/en active Active
- 2020-03-05 MX MX2021010545A patent/MX2021010545A/es unknown
- 2020-03-05 MA MA055201A patent/MA55201A/fr unknown
- 2020-03-05 AU AU2020232757A patent/AU2020232757A1/en active Pending
- 2020-03-05 JP JP2021552624A patent/JP2022524997A/ja active Pending
- 2020-03-05 EP EP20713496.6A patent/EP3934651A1/en active Pending
- 2020-03-05 KR KR1020217031644A patent/KR20210137087A/ko unknown
-
2021
- 2021-08-31 IL IL285999A patent/IL285999A/en unknown
-
2022
- 2022-06-30 US US17/854,443 patent/US11896595B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022524997A (ja) | 2022-05-11 |
| CA3132371A1 (en) | 2020-09-10 |
| CN114007621A (zh) | 2022-02-01 |
| IL285999A (en) | 2021-10-31 |
| AU2020232757A1 (en) | 2021-10-07 |
| EA202192426A1 (ru) | 2021-11-15 |
| US11896595B2 (en) | 2024-02-13 |
| WO2020181034A1 (en) | 2020-09-10 |
| EP3934651A1 (en) | 2022-01-12 |
| MA55201A (fr) | 2022-01-12 |
| MX2021010545A (es) | 2021-11-17 |
| US20200281931A1 (en) | 2020-09-10 |
| US20220331325A1 (en) | 2022-10-20 |
| KR20210137087A (ko) | 2021-11-17 |
| US11406640B2 (en) | 2022-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285999A (en) | jak1 inhibitor pathway for the treatment of impaired chronic lung allograft function | |
| IL276725A (en) | JAK1 pathway inhibitors for the treatment of cytokine-related disorders | |
| IL289534A (en) | Inhibitors of parp1 | |
| IL279260A (en) | KDM1A inhibitors for the treatment of diseases | |
| IL284034A (en) | JAK1 pathway inhibitors for the treatment of gastrointestinal disease | |
| IL291452A (en) | Dosage forms for tyk2 inhibitors | |
| IL287902A (en) | Methods of administering certain vmat2 inhibitors | |
| IL290011A (en) | Ezh2 inhibition in combination therapies for cancer treatment | |
| IL282007A (en) | Medicine to treat chronic cough | |
| IL287717A (en) | Pyrrolopyridines are converted as jak inhibitors | |
| IL292657A (en) | Therapeutic history of interleukin-22 | |
| IL308476A (en) | Inhibitors of the menin-mil interaction | |
| IL280770A (en) | Substances of the diazabicyclooctanone type for use as serine inhibitors in lactamase | |
| EP3844166C0 (en) | SUBSTITUTED MACROCYCLES USEFUL AS KINASE INHIBITORS | |
| IL292690A (en) | mrgprx2 antagonists for the treatment of inflammatory disorders | |
| IL308216A (en) | Jak1 pathway inhibitors for the treatment of prurigo nodularis | |
| IL291785A (en) | 6,1- Naphthyridine-converted inhibitors of cdk5 | |
| PT3510167T (pt) | Métodos e composições para prever disfunção crónica de aloenxerto pulmonar | |
| IL288472A (en) | Tetracyclic compounds as cdc7 inhibitors | |
| IL281599A (en) | TYK2 kinase inhibitors | |
| PT3645735T (pt) | Métodos e composições para prever disfunção crónica de aloenxerto pulmonar | |
| IL286533A (en) | Compounds for use in the treatment of adcy5-related dyskinesia | |
| IL282739A (en) | Compounds and methods for treating smooth muscle dysfunction | |
| GB201814067D0 (en) | Compounds for the inhibition of cyclophilins | |
| SG10201902000YA (en) | Isthmin 1 for treatment of lung inflammation |